MedTrace Logo

Prevalence and Impact on QoL From Ototoxicity in Cancer Survivors

NCT04270916 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2020-03-25

No results posted yet for this study

Summary

This study will involve collaborating with oncologists in the post-chemotherapy follow-up appointments. The participants who wish to consent to this study will then answer 3 short questionnaires (THI, HHIA and SF-36) about hearing loss, tinnitus and quality of life. The audiologist or the researcher, under the supervision of an audiologist, will then perform a simple, non-invasive hearing test on the participant. Should the participant have a hearing loss, they will be advise to seek help from their General Practitioner.

Conditions

  • Hearing Loss, Sensorineural
  • Tinnitus, Subjective
  • Cancer
  • Chemotherapeutic Toxicity

Interventions

DIAGNOSTIC_TEST

High frequency pure tone audiometry

Hearing test carried out routinely, non invasive

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • International Stem Cell Forum

    collaborator OTHER

  • University of Nottingham

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04270916 on ClinicalTrials.gov